Hasenkamp, Justin

[["dc.bibliographiccitation.firstpage","467"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","468"],["dc.bibliographiccitation.volume","48"],["dc.contributor.author","Dicke, C. C."],["dc.contributor.author","Kertesz, Andras"],["dc.contributor.author","Henke, R. P."],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Jung, Werner"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Wulf, Gerald G."],["dc.date.accessioned","2018-11-07T09:27:21Z"],["dc.date.available","2018-11-07T09:27:21Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1038/bmt.2012.165"],["dc.identifier.isi","000316920100026"],["dc.identifier.pmid","22964591"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30514"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0268-3369"],["dc.title","Retroperitoneal fibrosis as manifestation of chronic GVHD after allogeneic hematopoietic SCT"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2438"],["dc.bibliographiccitation.issue","14"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.lastpage","2447"],["dc.bibliographiccitation.volume","116"],["dc.contributor.author","Dreger, Peter"],["dc.contributor.author","Doehner, Hartmut"],["dc.contributor.author","Ritgen, Matthias"],["dc.contributor.author","Boettcher, Sebastian"],["dc.contributor.author","Busch, Raymonde"],["dc.contributor.author","Dietrich, Sascha"],["dc.contributor.author","Bunjes, Donald W."],["dc.contributor.author","Cohen, Sandra"],["dc.contributor.author","Schubert, Joerg"],["dc.contributor.author","Hegenbart, Ute"],["dc.contributor.author","Beelen, Dietrich"],["dc.contributor.author","Zeis, Matthias"],["dc.contributor.author","Stadler, Michael"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Uharek, Lutz"],["dc.contributor.author","Scheid, Christof"],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Zenz, Thorsten"],["dc.contributor.author","Winkler, Dirk"],["dc.contributor.author","Hallek, Michael"],["dc.contributor.author","Kneba, Michael"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Stilgenbauer, Stephan"],["dc.date.accessioned","2018-11-07T08:38:06Z"],["dc.date.available","2018-11-07T08:38:06Z"],["dc.date.issued","2010"],["dc.description.abstract","The purpose of this prospective multicenter phase 2 trial was to investigate the long-term outcome of reduced-intensity conditioning allogeneic stem cell transplantation (alloSCT) in patients with poor-risk chronic lymphocytic leukemia. Conditioning was fludarabine/cyclophosphamide-based. Longitudinal quantitative monitoring of minimal residual disease (MRD) was performed centrally by MRD-flow or real-time quantitative polymerase chain reaction. One hundred eligible patients were enrolled, and 90 patients proceeded to alloSCT. With a median follow-up of 46 months (7-102 months), 4-year nonrelapse mortality, event-free survival (EFS) and overall survival (OS) were 23%, 42%, and 65%, respectively. Of 52 patients with MRD monitoring available, 27 (52%) were alive and MRD negative at 12 months after transplant. Four-year EFS of this subset was 89% with all event-free patients except for 2 being MRD negative at the most recent assessment. EFS was similar for all genetic subsets, including 17p deletion (17p-). In multivariate analyses, uncontrolled disease at alloSCT and in vivo T-cell depletion with alemtuzumab, but not 17p-, previous purine analogue refractoriness, or donor source (human leukocyte antigen-identical siblings or unrelated donors) had an adverse impact on EFS and OS. In conclusion, alloSCT for poor-risk chronic lymphocytic leukemia can result in long-term MRD-negative survival in up to one-half of the patients independent of the underlying genomic risk profile. This trial is registered at http://clinicaltrials.gov as NCT00281983. (Blood. 2010;116(14):2438-2447)"],["dc.description.sponsorship","Roche; Novartis; Bayer; Amgen; Celgene; Glaxo Smith-Kline"],["dc.identifier.doi","10.1182/blood-2010-03-275420"],["dc.identifier.isi","000282645900010"],["dc.identifier.pmid","20595516"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18693"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.relation.issn","0006-4971"],["dc.title","Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1127"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1133"],["dc.bibliographiccitation.volume","96"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:22:22Z"],["dc.date.available","2018-11-07T10:22:22Z"],["dc.date.issued","2017"],["dc.description.abstract","Graft-versus-host disease (GvHD) still belongs to the major challenges after allogeneic hematopoietic stem cell transplantation (HSCT). Immune-suppressive therapy against GvHD is a double-edged sword due to risk of infections and relapse. The ability to adapt prophylactic treatment according to the probability of severe GvHD would be an essential advantage for the patients. We analyzed different biomarkers for their potential to predict the development of GvHD in 28 patients who underwent allogeneic HSCT. Blood was taken once directly after hematopoietic engraftment. In this study, patients were monitored for 12 months after HSCT for the occurrence of acute GvHD or acute/chronic GvHD overlap syndrome. Soluble IL-2 receptor and CD4/CD8 T cell ratio were independently associated with the occurrence of GvHD in the observation period. However, the largest area under the receiver operating characteristic curve with 0.90 was observed when a 5-parameter biomarker score based on CD4(+) T cells, CD8(+) T cells, CD19(-) CD21(+) precursor B cells, CD4/CD8 T cell ratio, and soluble IL-2 receptor was used to predict GvHD. In addition, CD8(+) T cell levels above 2.3% of all mononuclear cells after engraftment may predict relapse-free survival at least for 12 months. In summary, we found a new biomarker panel for prediction of GvHD which is featured by established laboratory assays and high statistical significance. In order to introduce the biomarker panel into routine clinical protocols, we suggest performing a larger multi-center study."],["dc.identifier.doi","10.1007/s00277-017-2999-5"],["dc.identifier.isi","000403078900008"],["dc.identifier.pmid","28447161"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42255"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-0584"],["dc.relation.issn","0939-5555"],["dc.title","Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2476"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Leukemia & Lymphoma"],["dc.bibliographiccitation.lastpage","2480"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Hellige, Niels"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Jung, Wolfram"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Binder, Mascha"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Bacher, Ulrike"],["dc.date.accessioned","2020-12-10T18:43:56Z"],["dc.date.available","2020-12-10T18:43:56Z"],["dc.date.issued","2016"],["dc.identifier.doi","10.3109/10428194.2016.1151510"],["dc.identifier.eissn","1029-2403"],["dc.identifier.issn","1042-8194"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78273"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","536"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Experimental Hematology"],["dc.bibliographiccitation.lastpage","546"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Schroers, Roland"],["dc.contributor.author","Hildebrandt, Y."],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Lieber, A."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Piesche, Matthias"],["dc.date.accessioned","2018-11-07T10:48:24Z"],["dc.date.available","2018-11-07T10:48:24Z"],["dc.date.issued","2004"],["dc.description.abstract","Objective. Genetic modification of effector lymphocytes, such as T cells and natural killer (NK) cells, is essential for many approaches to gene-based immunotherapy of cancer. However, transduction of lymphocytes has proven difficult by currently available gene transfer methods. Previous studies have shown that chimeric fiber-modified Ad5/F35 adenoviral vectors are able to efficiently transduce hematopoietic cells including immature progenitors. In this study, we examined the gene transfer into T lymphocytes and NK cells using Ad5/F35 compared with conventional Ad5 adenovectors. Methods. Primary T and NK cells were isolated from healthy donors' peripheral blood leukocytes by immunomagnetic selection. Cell lines and primary lymphocytes were transduced with replication-defective Ad5/F35 and Ad5, both containing a GFP reporter gene under the control of a CMV promoter. Transduction efficiencies were monitored by flow cytometry. The function of transduced lymphocytes was assessed by analysis of proliferative responses to mitogenic agents and in mixed leukocyte reactions. Results. Transgene expression was detected in up to 45% of primary CD3+ T lymphocytes and in up to 60% of primary NK cells using Ad5/F35. In contrast, conventional Ad5 transduced less than 8% and 5% of primary T cells and NK cells, respectively. Transduction efficiencies were similar in CD4+ and CD8+ T lymphocytes, and transgene expression could be detected for up to seven days. Activation of T cells significantly enhanced the efficiency of Ad5/F35-mediated gene transfer. Adenoviral transduction of lymphocytes did not result in any impairment of proliferative functions. Conclusion. The results of this study demonstrate that both T lymphocytes and NK cells can be transduced by chimeric Ad5/F35 adenoviral vectors. (C) 2004 International Society for Experimental Hematology. Published by Elsevier Inc."],["dc.identifier.doi","10.1016/j.exphem.2004.03.010"],["dc.identifier.isi","000222175700004"],["dc.identifier.pmid","15183894"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/48183"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","0301-472X"],["dc.title","Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","Advances in Hematology"],["dc.bibliographiccitation.lastpage","7"],["dc.bibliographiccitation.volume","2020"],["dc.contributor.author","Schmalz, Gerhard"],["dc.contributor.author","Tulani, Lulzim"],["dc.contributor.author","Busjan, Rilana"],["dc.contributor.author","Haak, Rainer"],["dc.contributor.author","Kottmann, Tanja"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Ziebolz, Dirk"],["dc.date.accessioned","2021-06-01T10:47:44Z"],["dc.date.available","2021-06-01T10:47:44Z"],["dc.date.issued","2020"],["dc.description.abstract","This retrospective pilot study aimed to detect whether remaining dental/periodontal treatment need and periodontal inflammation after dental clearance would be associated with the initial therapy outcome of adult patients with acute leukemia undergoing induction chemotherapy. Different parameters were assessed from the patients’ records: initial blood parameters, blood parameters during initial chemotherapy, leukemia/therapy related complaints, duration of fever, microbiological findings (blood and urine), as well as patients’ survival. Dental treatment need was defined as the presence of at least one carious tooth; periodontal treatment need was determined by the presence of probing depth ≥3.5 mm in at least two sextants. To reflect periodontal inflammation, the periodontal inflamed surface area (PISA) was applied. Thirty-nine patients were included. A dental treatment need of 75% and periodontal treatment need of 76% as well as an average PISA of 153.18 ± 158.09 were found. Only two associations were detected: periodontal treatment need was associated with thrombocyte count after 7 days ( p = 0.03 ), and PISA was associated with erythrocyte count three days after induction of therapy ( p = 0.01 ). It can be concluded that remaining dental and periodontal treatment need as well as periodontal inflammation after dental clearance is not associated with the outcome of induction therapy in adult patients with acute leukemia."],["dc.identifier.doi","10.1155/2020/6710906"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85702"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1687-9112"],["dc.relation.issn","1687-9104"],["dc.title","Dental and Periodontal Treatment Need after Dental Clearance Is Not Associated with the Outcome of Induction Therapy in Patients with Acute Leukemia: Results of a Retrospective Pilot Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","105"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Acta Haematologica"],["dc.bibliographiccitation.lastpage","110"],["dc.bibliographiccitation.volume","144"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Szuszies, Christoph Johannes"],["dc.contributor.author","Koch, Raphael"],["dc.contributor.author","Wulf, Gerald Georg"],["dc.date.accessioned","2021-04-14T08:29:58Z"],["dc.date.available","2021-04-14T08:29:58Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1159/000506302"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83051"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1421-9662"],["dc.relation.issn","0001-5792"],["dc.title","Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","218"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Scandinavian Journal of Immunology"],["dc.bibliographiccitation.lastpage","229"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Hasenkamp, J."],["dc.contributor.author","Borgerding, A."],["dc.contributor.author","Uhrberg, M."],["dc.contributor.author","Falk, C."],["dc.contributor.author","Chapuy, Björn"],["dc.contributor.author","Wulf, G."],["dc.contributor.author","Jung, W."],["dc.contributor.author","Trümper, L."],["dc.contributor.author","Glass, B."],["dc.date.accessioned","2021-06-01T10:47:17Z"],["dc.date.available","2021-06-01T10:47:17Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1111/j.1365-3083.2007.02058.x"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85548"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","1365-3083"],["dc.relation.issn","0300-9475"],["dc.title","Self-tolerance of Human Natural Killer Cells Lacking Self-HLA-specific Inhibitory Receptors"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HLA"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Budde, Holger"],["dc.contributor.author","Papert, Susanne"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Reichardt, Holger Michael"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.date.accessioned","2018-11-07T10:23:29Z"],["dc.date.available","2018-11-07T10:23:29Z"],["dc.date.issued","2017"],["dc.format.extent","362"],["dc.identifier.isi","000400973300051"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42466"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Wiley"],["dc.publisher.place","Hoboken"],["dc.relation.issn","2059-2310"],["dc.relation.issn","2059-2302"],["dc.title","SCREENING FOR A BIOMARKER PANEL FOR PREDICTION OF GRAFT VERSUS HOST DISEASE IN HUMANS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1307"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1315"],["dc.bibliographiccitation.volume","90"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Sahlmann, Carsten Oliver"],["dc.contributor.author","Lakhani, Vijai J."],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Glass, Bertram"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Meller, Johannes"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Griesinger, Frank"],["dc.date.accessioned","2018-11-07T08:50:15Z"],["dc.date.available","2018-11-07T08:50:15Z"],["dc.date.issued","2011"],["dc.description.abstract","A phase II trial evaluated safety, feasibility and efficacy of a sequential tandem approach combining myeloablative BEAM chemotherapy and autologous stem cell transplantation (ASCT) with myeloablative radioimmunotherapy (HD-RIT), with I-131-anti-CD20 antibody (I-131-rituximab), followed by a second ASCT in patients with relapsed or refractory CD20+ B-cell lymphoma. According to protocol, 16 patients with relapsed (n=14) and refractory (n=2) CD20+ B-cell lymphoma received salvage therapy with rituximab and Dexa-BEAM, followed by BEAM (HD chemotherapy) and high-dose myeloablative radioimmunotherapy 2-6 months after BEAM. Nine of 16 patients received HD-RIT; seven patients were excluded before HD-RIT because of toxicity or progressive disease. Disease histologies were follicular lymphoma (FL) grades 1 and 2 (n=4), transformed follicular (FL 3b; n=6), diffuse large B-cell (DLBCL; n=4), mantle cell (n=1) and marginal zone lymphoma (n=1). After a median follow-up of 50.4 months for OS and 39.7 months for progression-free survival (PFS), estimated 4-year OS and PFS were 67% and 64%, respectively. The estimated 4-year OS and PFS for patients with FL were 80% and 78%, respectively. Toxicity was significant, including one fatal outcome due to pneumonitis. Tandem transplants consisting of HD chemotherapy followed by HD-RIT with I-131-coupled anti-CD20 are manageable and effective but toxic treatment modalities for relapsed poor prognosis CD20+ B-NHL."],["dc.identifier.doi","10.1007/s00277-011-1199-y"],["dc.identifier.isi","000296730300008"],["dc.identifier.pmid","21360108"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/7836"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21653"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with I-131-anti-CD20 antibody and stem cell rescue"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]